UnitedHealth Stock Forecast: Trending Views From Top Analysts

UnitedHealth (UNH) stock has risen 7.9% over the past week, 26.6% over the past month, and 30.9% over the past year. Wall Street’s analysts are moderately bullish, forecasting a modest decrease toward a 12‑month price target of $386.86 from the last close at $396.39, reflecting a “Moderate Buy” consensus overall.

Analyst Kevin Fischbeck of BofA Securities reiterated a Hold rating on UNH on May 12, 2026, while raising his price objective to $420.00, slightly above the current market price. His new target implies only limited upside near term, as he stays neutral pending more clarity on 2028 Medicare Advantage rate dynamics.

Fischbeck’s report highlights a confident management tone at the recent BofA Healthcare Conference, with leadership expecting to restore margins to at least the low end of target ranges by 2028. Early April data show that medical cost trends remain well controlled, but management wants to see second‑quarter figures before declaring victory.

UnitedHealth’s Medicaid, OptumHealth, and Medicare Advantage businesses are all expected to move back toward long‑term margin goals by 2028, even if that means exiting some weaker Medicaid state contracts. OptumHealth is projected to deliver percentage‑point margin improvement from 2027, and Medicare Advantage margins are seen migrating into the upper half of the 2–4% range by 2028.

The company is also rolling out a transparent pharmacy benefit model that passes through 100% of rebates while maintaining its 3–5% PBM margin target, supported by early contracting experience. Management believes heavy investment in AI can significantly cut general and administrative costs, supporting its long‑term 13–16% EPS growth algorithm, driven by capital deployment, revenue expansion, and margin improvement.

Never miss a stock rating. Find all the latest ratings on TipRanks’ Top Wall Street Analysts page.